These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31308062)

  • 41. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
    Frumovitz M; Westin SN; Salvo G; Zarifa A; Xu M; Yap TA; Rodon AJ; Karp DD; Abonofal A; Jazaeri AA; Naing A
    Gynecol Oncol; 2020 Sep; 158(3):570-575. PubMed ID: 32534809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
    Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
    Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
    Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
    Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
    Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
    Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Maitland ML; Sachdev JC; Sharma MR; Moreno V; Boni V; Kummar S; Stringer-Reasor E; Lakhani N; Moreau AR; Xuan D; Li R; Powell EL; Jackson-Fisher A; Bowers M; Alekar S; Xin X; Tolcher AW; Calvo E
    Clin Cancer Res; 2021 Aug; 27(16):4511-4520. PubMed ID: 34083232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies.
    Boyle J; Craciunescu O; Steffey B; Cai J; Chino J
    Gynecol Oncol; 2014 Nov; 135(2):239-43. PubMed ID: 25192879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
    Secord AA; Havrilesky LJ; Carney ME; Soper JT; Clarke-Pearson DL; Rodriguez GC; Berchuck A
    Int J Clin Oncol; 2007 Feb; 12(1):31-6. PubMed ID: 17380438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
    Smith DC; Chugh R; Patnaik A; Papadopoulos KP; Wang M; Kapoun AM; Xu L; Dupont J; Stagg RJ; Tolcher A
    Invest New Drugs; 2019 Aug; 37(4):722-730. PubMed ID: 30591982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
    Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
    Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
    Seiden MV; Gordon AN; Bodurka DC; Matulonis UA; Penson RT; Reed E; Alberts DS; Weems G; Cullen M; McGuire WP
    Gynecol Oncol; 2006 Apr; 101(1):55-61. PubMed ID: 16260029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
    Ramirez PT; Landen CN; Coleman RL; Milam MR; Levenback C; Johnston TA; Gershenson DM
    Gynecol Oncol; 2008 Jan; 108(1):68-71. PubMed ID: 17905421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
    Vaidya AP; Parnes AD; Seiden MV
    Curr Treat Options Oncol; 2005 Mar; 6(2):103-14. PubMed ID: 15717992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
    Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
    Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
    Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
    Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
    Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
    Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.